Chloé Cantero1, Dan Adler2, Patrick Pasquina1, Christophe Uldry3, Bernard Egger3, Maura Prella4, Alain B Younossian5, Paola M Soccal2, Jean-Louis Pépin6, Jean-Paul Janssens7. 1. Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland. 2. Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland. 3. Division of Pulmonary Diseases and Pulmonary Rehabilitation Center, Rolle Hospital Rolle, Vaud, Switzerland. 4. Division of Pulmonary Diseases, Lausanne University Hospital (CHUV), Lausanne, Switzerland. 5. Division of Pulmonary Diseases and Intensive Care, La Tour Hospital, Meyrin, Geneva, Switzerland. 6. HP2 laboratory, Inserm U1042 unit, University Grenoble Alps, Grenoble, France; EFCR laboratory, Thorax and vessels, Grenoble Alps University Hospital, Grenoble, France. 7. Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: jean-paul.janssens@hcuge.ch.
Abstract
BACKGROUND: Noninvasive ventilation (NIV) is standard of care for chronic hypercapnic respiratory failure, but indications, devices, and ventilatory modes are in constant evolution. RESEARCH QUESTION: To describe changes in prevalence and indications for NIV over a 15-year period; to provide a comprehensive report of characteristics of the population treated (age, comorbidities, and anthropometric data), mode of implementation and follow-up, devices, modes and settings used, physiological data, compliance, and data from ventilator software. STUDY DESIGN AND METHODS: Cross-sectional observational study designed to include all subjects under NIV followed by all structures involved in NIV in the Cantons of Geneva and Vaud (1,288,378 inhabitants). RESULTS: A total of 489 patients under NIV were included. Prevalence increased 2.5-fold since 2000 reaching 38 per 100,000 inhabitants. Median age was 71 years, with 31% being > 75 years of age. Patients had been under NIV for a median of 39 months and had an average of 3 ± 1.8 comorbidities; 55% were obese. COPD (including overlap syndrome) was the most important patient group, followed by obesity hypoventilation syndrome (OHS) (26%). Daytime Paco2 was most often normalized. Adherence to treatment was satisfactory, with 8% only using their device < 3.5 h/d. Bilevel positive pressure ventilators in spontaneous/timed mode was the default mode (86%), with a low use of autotitrating modes. NIV was initiated electively in 50% of the population, in a hospital setting in 82%, and as outpatients in 15%. INTERPRETATION: Use of NIV is increasing rapidly in this area, and the population treated is aging, comorbid, and frequently obese. COPD is presently the leading indication followed by OHS. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04054570; URL: www.clinicaltrials.gov.
BACKGROUND: Noninvasive ventilation (NIV) is standard of care for chronic hypercapnic respiratory failure, but indications, devices, and ventilatory modes are in constant evolution. RESEARCH QUESTION: To describe changes in prevalence and indications for NIV over a 15-year period; to provide a comprehensive report of characteristics of the population treated (age, comorbidities, and anthropometric data), mode of implementation and follow-up, devices, modes and settings used, physiological data, compliance, and data from ventilator software. STUDY DESIGN AND METHODS: Cross-sectional observational study designed to include all subjects under NIV followed by all structures involved in NIV in the Cantons of Geneva and Vaud (1,288,378 inhabitants). RESULTS: A total of 489 patients under NIV were included. Prevalence increased 2.5-fold since 2000 reaching 38 per 100,000 inhabitants. Median age was 71 years, with 31% being > 75 years of age. Patients had been under NIV for a median of 39 months and had an average of 3 ± 1.8 comorbidities; 55% were obese. COPD (including overlap syndrome) was the most important patient group, followed by obesity hypoventilation syndrome (OHS) (26%). Daytime Paco2 was most often normalized. Adherence to treatment was satisfactory, with 8% only using their device < 3.5 h/d. Bilevel positive pressure ventilators in spontaneous/timed mode was the default mode (86%), with a low use of autotitrating modes. NIV was initiated electively in 50% of the population, in a hospital setting in 82%, and as outpatients in 15%. INTERPRETATION: Use of NIV is increasing rapidly in this area, and the population treated is aging, comorbid, and frequently obese. COPD is presently the leading indication followed by OHS. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04054570; URL: www.clinicaltrials.gov.
Authors: A Léotard; M Delorme; S Hartley; C Khouri; M Lebret; F Lofaso; J-L Pepin; J-C Borel Journal: Sleep Breath Date: 2022-06-20 Impact factor: 2.816
Authors: Mathieu Delorme; Karl Leroux; Ghilas Boussaid; Marius Lebret; Helene Prigent; Antoine Leotard; Bruno Louis; Frédéric Lofaso Journal: Arch Bronconeumol Date: 2021-02-02 Impact factor: 4.872
Authors: Miguel Angel Martinez-García; Carmen Villa; Yadira Dobarganes; Rosa Girón; Luis Maíz; Marta García-Clemente; Oriol Sibila; Rafael Golpe; Juan Rodríguez; Esther Barreiro; Juan Luis Rodriguez; Rosario Menéndez; Concepción Prados; David de la Rosa; Casilda Olveira Journal: Arch Bronconeumol (Engl Ed) Date: 2020-02-17 Impact factor: 4.872
Authors: Nicholas S Hill; Gerard J Criner; Richard D Branson; Bartolome R Celli; Neil R MacIntyre; Amen Sergew Journal: Chest Date: 2021-07-30 Impact factor: 9.410